On Demand

Accurate and efficient detection of the ALK gene rearrangement in NSCLC

Professor John Gosney

After highlighting how lung cancer biopsy reports have changed dramatically within 10 years, Prof. John Gosney delves into our understanding behind the ALK gene and the gold-standard method to detect the ALK gene rearrangement.

On Demand

The use of XALKORI® within ROS1+ advanced NSCLC

Dr Rohit Lal

Dr Rohit Lal explains the use of Xalkori in ROS1+ advanced NSCLC through PROFILE 10011 study data before presenting real world data provided through a ROS1 clinical case study.

On Demand

Accurate and efficient detection of the ROS1 gene rearrangement in NSCLC

Professor John Gosney

After highlighting how lung cancer biopsy reports have changed dramatically within 10 years, Prof. John Gosney delves into our understanding behind the ROS1 gene and the gold-standard method to detect the ROS1 gene rearrangement.

On Demand

IBRANCE® (palbociclib) indication

Erling Thor Donnelly, PhD. Pfizer | Oncology Lead, Sweden & Nordics IBRANCE Collaboration Lead

Ibrance is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:1

• In combination with an aromatase inhibitor;
• In combination with fulvestrant in women who have received prior endocrine therapy.

In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.

References
1. IBRANCE Summary of Product Characteristics

On Demand

IBRANCE® (palbociclib) mode of action

Pfizer

IBRANCE works synergistically with ET to prevent cell proliferation2,3
IBRANCE acts downstream from ER2,3. It inhibits CDK 4/6 and helps to control cancer cell proliferation by inducing G1 arrest and reducing cell cycle progression2,3
IBRANCE in combination with ET results in increased and sustained cell cycle arrest compared with ET alone2,3

References:
1. IBRANCE Summary of Product Characteristics
2. Rocca A, et al. Expert Opin Pharmacother. 2014;15(3):407-20
3. Cadoo KA, et al. Breast Cancer: Targets and Therapy. 2014;6:123-33

On Demand

IBRANCE® (palbociclib) dosing

Erling Thor Donnelly, PhD. Pfizer | Oncology Lead, Sweden & Nordics IBRANCE Collaboration Lead

FBCs are the only monitoring requirement with IBRANCE.1* Prior to initiating treatment with IBRANCE, patients should have their full blood count, liver function tests and urea and electrolytes testing, as well as testing as clinically required throughout treatment.1

It is recommended to monitor FBCs on Days 1 and 15 of the first cycle and on Day 1 of each cycle thereafter.1

For patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles, FBCs for subsequent cycles should be monitored every 3 months, prior to the beginning of a cycle and as clinically indicated.

*Other tests as clinically required
1. IBRANCE Summary of Product Characteristics.

On Demand

Why vaccinate HIV positive adults?

Frances Chatham

Overview: This short video features lead practice nurse and trainer Frances Chatham talking about the British HIV Association (BHIVA) vaccination recommendation for Prevenar 13 (PCV 13).

On Demand

British HIV Association (BHIVA) Access and Re-imbursement

Frances Chatham

Overview: This short video features lead practice nurse and trainer Frances Chatham talking about access and reimbursement for Prevenar 13 (PCV13) associated with the BHIVA vaccination recommendation for PCV13. 

Considerations when selecting a treatment for 2nd line mRCC patients
On Demand

Considerations when selecting a 2nd line treatment for mRCC patients

Various speakers

Pfizer logo for various speakers

In this video, leading mRCC experts provide their views on how to select a 2nd line treatment for their mRCC patients. This interview was recorded on 23 June 2017.

Treatment selection in 2nd line mRCC
On Demand

Treatment selection in 2nd line mRCC

Dr Enrique Grande

Dr Enrique Grande

In this interview, Dr Enrique Grande provides his approach to treatment selection in 2nd line mRCC. In particular, he describes how he would use Inlyta in favourable risk patients and patients who had a long-lasting clinical benefit to a TKI in the 1st line setting. This interview was recorded on the 23 June 2017.